A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

NCT02337725 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
244
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda